medigraphic.com
ISSN 1561-3054 (Electronic)

2016, Number 3

Next >>

Rev Cubana Med Trop 2016; 68 (3)

Occult hepatitis B virus infection in hemodialysis patients

Sariego FS, Valdivia ME, Bello CM, Montalvo VMC, Bali A, Sánchez WM, Marrero SB, Rodríguez LLÁ

Language: Spanish
References: 31
Page: 179-190
PDF size: 174.18 Kb.


ABSTRACT

Introduction: occult hepatitis B virus infection is characterized by the presence of the viral genome and antibodies to the capside protein in serum or plasma (anti- HBc) that test negative for the infection marker.
Objectives: to detect the occult hepatitis B virus in hemodialysis patients and to identify the possible relationship between occult hepatitis B infection and hepatitis C virus infection and the epidemiological and demographic variables.
Methods: seventy thousand and nine serum samples from patients treated in 18 hemodialysis units were included. Serological markers for HBV infection, exposure and immunity were tested. Samples with negative HBsAg , positive anti-HBc and anti-HBs titers ‹ 50 IU/L were tested for detection of HBV-DNA and HCV markers.
Results: the prevalence of HBV infection and exposure were 6.9 % and 28.6 % respectively. In the group, 4.3 % of samples met occult hepatitis B infection criteria, the HBV-DNA was detected in 58.1 % (18/31) of the samples, with viral loads below 105 IU/mL. Overall occult hepatitis B infection prevalence was 2.5 % (18/709). There was no significant association among the analyzed variables.
Conclusions: occult hepatitis B infection was frequent in hemodialysis patients with low levels of anti-HBs mainly in those with non protected titers. This study supports the need of keeping the prevention strategies against parenterally transmitted viral hepatitis in dialysis units.


REFERENCES

  1. WHO Information Office: Fact Sheet WHO/204. [cited 22 Sept 2015]. 2000. Disponible en: http://www.who.int/inf-fs/en/fact204.html

  2. Raimondo G, Pollicino T, Romano L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris). 2010;58(4):254-7.

  3. Gerlich WH, Bremer CM, Saniewski M, Christian G, Schüttler CG, Wend U, et al. Occult hepatitis B virus infection: detection and significance. Dig Dis Sci. 2010;28:116-25.

  4. Thedja MD, Roni M, Harahap AR, Siregar NC, Ie SI, Muljono DH. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol Int. 2010;4(3):608-14.

  5. Ramezani A, Banifazl M, Eslamifar A, Aghakhani A. Serological pattern of anti- HBc alone infers occult hepatitis B virus infection in high-risk individuals in Iran. J Infect Dev Ctries. 2010;4(10):658-61.

  6. Jardim RN, Goncales NS, Pereira JS, Fais VC, Goncales FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis. 2008;12(4):300- 5.

  7. Bello M, Montalvo M, Rodríguez L, Sariego S, Verdasquera D, Vincent M, et al. Occult hepatitis B in Cuban HIV patients. Medicc Review 2011;13(2):32-7.

  8. Schmeltzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci. 2010;55(12):3328-35.

  9. Ballester J, Rivero R, Villaescusa R, Merlın JC, Arce AA, Castillo D, et al. Hepatitis C virus antibodies and other markers of blood-transfusion-transmitted infection in multi-transfused Cuban patients. J Clin Virol. 2005;34(2):S39-S46.

  10. Montalvo MC, Delgado G, Diaz M, Rodríguez L. Prevalence of hepatitis B virus markers and risk factors associated in haemodialysis patients from Havana City; 2002-2003. Nefrología. 2007;27(2):234-5.

  11. Rodríguez L, Montalvo MC, Sariego S, Bello M, Mora E, Kourí V, et al. Reacción en cadena de la polimerasa en tiempo real para la cuantificación del ADN del virus de la hepatitis B. Rev Cubana Med Trop. 2012 [citado 22 Sept 2015];64(3). Disponible en: http://bvs.sld.cu/revistas/mtr/v64n3_12/mtr09312.htm

  12. Fonte M. Hepatitis viral B: estrategias del programa e impacto. En: Taller Nacional de Hepatitis; La Habana, Cuba, 2010.

  13. Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patients population. Hepatol. 2004;40(5):1072-7.

  14. Paniagua R, Villasis-Keever A, Prado-Uribe MC, Ventura-García MD, Alcántara- Ortega G, Ponce de Leon SR, et al. Elevated prevalence of hepatitis B in Mexican hemodialysis patients. A multicentric survey. Arch Med Res. 2010;41(4):251-4.

  15. El-Ottol A, Elmanama A, Ayesh B. Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine. Virol J. 2010;7:210-7.

  16. Telaku S, Fejza H, Elezi Y, Bicaj T. Hepatitis B and C in dyalisis units in Kosova. Virol J. 2009;6:72-5.

  17. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003;63(6):2222-9.

  18. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009;24(5):1598-603.

  19. Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton) 2010;15(2):137-45.

  20. Gutiérrez-García M, Fernandez-Rodriguez C, Lledo-Navarro J, Buhigas-García I. Prevalence of occult hepatitis B virus infection. World J Gastroenterol. 2011;17(12):1538-42.

  21. González-Griego M, Pentón E, Delgado G, Pérez J, Izquierdo M, Garcia G. Impact of an anti-hepatitis B virus (HBV) immunization program in patients undergoing dialysis in Havana, Cuba. Invest Clin. 2000;41(4):237-44.

  22. Roman S, Panduro A, Aguilar-Gutiérrez Y, Maldonado M, Vazquez-VanDyck M, Martinez-Lopez E, et al. A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review. Hepatol Int. 2009;3:343-55.

  23. Mina P, Georgiadou SP, Rizos C, Dalekos GN, Rigopoulou EI. Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. World J Gastroenterol. 2010;16(2):225-31.

  24. Fabrizi F, Messa P, Lunghi G, Aucella F, Bisegna S, Mangano S, et al. Occult hepatitis B in dialysis patients: a multicentre survey. Aliment Pharmacol Ther. 2005;21:1341-7.

  25. Montalvo MC. Perfil seroepidemiológico del virus de hepatitis B en pacientes hemodializados de Ciudad de la Habana. Tesis de Maestría en Virología. Departamento de Virología. Instituto de Medicina Tropical Pedro Kourí, La Habana, 2004.

  26. Kanbay M, Gur G, Akcay A, Selcuk H, Yilmaz U, Arslan H, et al. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients? Dig Dis Sci. 2006;51(11):1962-6.

  27. Fabrizi F, Marzano A, Messa, P, Martin, P, Lampertico, P. Hepatitis B virus infection in the dialysis population: current perspectives. Int J Artif Organs. 2008;31(5):386-94.

  28. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail. 2006;28(8):729-35.

  29. Sav T, Gursoy S, Torun E, Sav NM, Unal A, Oymak O, et al. Occult HBV infection in continuous ambulatory peritoneal dialysis and hemodialysis patients. Ren Fail. 2010;32(1):74-7.

  30. Motta J, Mello F, Lago B, Perez R, Gomes S, Figueiredo F. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis. J Gastroenterol Hepatol. 2010;25:101-6.

  31. Yuan Q, Ou SH, Chen CR, Ge SX, Pei B, Chen QR, et al. Molecular characteristics of occult hepatitis B virus from blood donors in southeast China. J Clin Microbiol. 2010;48(2):357-62.




2020     |     www.medigraphic.com